Open AccessThe economic and humanistic burden of patients in receipt of current available therapies for nAMD
Author(s) -
Dena H. Jaffe,
Wing Chan,
Vladimir Bezlyak,
A Skelly
Publication year - 2018
Publication title -
journal of comparative effectiveness research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.567
H-Index - 23
eISSN - 2042-6313
pISSN - 2042-6305
DOI - 10.2217/cer-2018-0058
Subject(s) - medicine , receipt , macular degeneration , cohort , quality of life (healthcare) , population , cohort study , health care , ranibizumab , ophthalmology , bevacizumab , environmental health , nursing , computer science , economics , economic growth , chemotherapy , world wide web
Aim: To determine the economic and humanistic burden of neovascular age-related macular degeneration (nAMD) in a cohort of patients treated with anti-VEGF in Europe and the US. Patients & methods: 79 respondents from the EU and 63 from the US with a self-reported diagnosis of nAMD and in current receipt of treatment, as reported in an international, general population survey, were compared with non-nAMD controls. Results: Anti-VEGF-treated nAMD patients in the EU had a greater utilization of healthcare resources, poorer quality of life and greater overall activity impairment versus non-nAMD controls. In the US cohort, treated nAMD patients had significantly greater resource utilization for ophthalmologist visits only. Conclusion: The burden of care associated with nAMD on EU and US healthcare systems, and on patients who are in receipt of nAMD therapy, is significant and likely to be unsustainable.